Ongoing Clinical Trials

• A Study of LY3154207 in Participants With Parkinson's Disease Dementia (PRESENCE) (NCT03305809)
• Clinical Effect Durability of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure (NCT03829657)

• Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3) Protocol (NCT02854033)
• Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease (TANGO) (NCT03352557)
• A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease (NCT03443973)
• Study of BHV-4157 in Alzheimer's Disease (03605667) 

• A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (Generation S1) (NCT02565511)
• A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD) (NCT03131453) 

• A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies", Protocol E2027-G000-201  (NCT 03467152)

There are currently no trials available. 

There are currently no trials available. 

The Brain and Body Donation Program

Study Goals: This study is designed to be able to compare the brain function of living adults with tissue that they donate when they pass away.

What’s Involved: Participants will be seen in person once per year to complete assessments of neurological and motor function, sense of smell, memory and thinking, sleep and general medical health. When participants pass away, a transport service will bring them to the Institute for autopsy. The tissues that they donate will be used to provide a diagnostic autopsy report and will be stored for future use by researchers locally and throughout the world to study aging, cancer, Parkinson’s and Alzheimer’s (as well as related conditions).

Eligible patients will:

• Have a diagnosis of Parkinson’s, Alzheimer’s disease, dementia with Lewy bodies or REM sleep behavior disorder
• Reside (at least 6 months per year) in Maricopa County
• Be willing to participate in annual assessments at the Institute    

To learn more contact us at (623) 832-6500.